Ocelot Bio, Inc., is a clinical-stage biopharmaceutical company dedicated to bringing meaningful therapeutic interventions to patients in dire need due to complications of decompensated (advanced) cirrhosis, in particular hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites.